EU/3/07/445: Orphan designation for the prevention of corneal graft rejection

Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)

Table of contents

Overview

On 17 April 2007, orphan designation (EU/3/07/445) was granted by the European Commission to Gene Signal SAS, France, for antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT) for the prevention of corneal graft rejection.

Key facts

Active substance
Antisense oligonucleotide (TATCCGGAGGGCTCGCCATGCTGCT)
Intended use
Prevention of corneal graft rejection
Orphan designation status
Positive
EU designation number
EU/3/07/445
Date of designation
17/04/2007
Sponsor
Gene Signal SAS
4, rue Pierre Fontaine
91000 Evry
France
Telephone: + 33 1 55 60 12 55
Telefax: + 33 1 55 60 12 56
E-mail: salman.almahmood@wanadoo.fr

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating